G1 Therapeutics Inc.

Plus: Glasspool to lead VarmX, Novartis vet Eissa joins Cellares and updates from Mestag, Andera, Incyclix and more

Plus: Coya promotes Arun Swaminathan to CEO, and updates from Tempest and Incyclix

Plus: Denmark-based Pharmacosmos buys G1, obtaining myelosuppression drug

Plus: New data from Wave, G1 and Jazz

Plus: Enterprise hires Renu Gupta as CMO, and chairman retires at TScan

Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more

Plus: Jami Rubin joins Arch, and updates from Exo, Harbinger, Twist and more

Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more

Plus: Treeline takes rights to Hengrui’s EZH2 and updates from Cerevance, G1, Frequency, Ocular, Biocon and more 

AstraZeneca’s camizestrant data cap progress in oral SERDs, a class that is figuring out how to demonstrate benefit against changing competition